Fully funded by 
Content independently selected
Strategies to better tailor effective treatments are needed.
Bisphosphonates, denosumab are preferred.
Early assessment, support important for patients older than 50 years.
Olaratumab is no longer recommended as first-line treatment.
Consider alternative treatment options to olaratumab since available stock will expire by April 2020.
Can legalization help counteract the opioid crisis?
By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.
Reductions in mortality driven by lung cancer in men, breast cancer in women.
Data from the ongoing dose-escalation stage of a first-in-human phase 1/2 clinical study.
CRISPR-Cas9 has been used for the first time to successfully edit the latency-associated nuclear antigen (LANA) of the KSHV virus, and reduce viral episome burden in infected cells
A pooled analysis of data from SMART and START studies allows calculating the magnitude and quality of benefits of life-long antiretroviral treatment
"Site-agnostic" oral therapy for tumors with NTRK gene fusion.
A more flexible and tailored approach to trial recruitment could help 12 to 25-year-old patients by giving them access to new cancer treatments.
The establishment of a national reference centre in France with multidisciplinary committees (RCP) has markedly improved outcomes for sarcoma patients.
Oncologists should replace the Internet as a primary source of information.
Drug interactions more common with TKIs than chemotherapy.
The new review process will streamline FDA evaluation of other oncology drugs.
